Drug Trial Radar · NCT07795567
A Study Comparing Ivermectin Cream 1%, Soolantra™ Cream 1%, PrROSIVER® Cream1% to Placebo Control in the Treatment of Moderate to Severe Facial Rosacea.
Last checked: Nov 20, 2026Latest source record: Aug 31, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
865
Actual
Start
Dec 9, 2025
Primary completion
Jun 24, 2026
Study completion Jun 24, 2026
Sponsor
- Lead sponsor
- Sun Pharmaceutical Industries, Inc.Industry
- Sponsor type
- Industry
- First posted
- Aug 31, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to evaluate and demonstrate the therapeutic equivalence and safety of Ivermectin Cream 1%, Soolantra™ Cream 1%, PrRosiver® Cream 1% \& to Placebo for the treatment of moderate to severe facial rosacea.
Conditions
- Rosacea
Interventions
Ivermectin Cream 1%Drug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Soolantra™ Cream 1%Drug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
PrRosiver® Cream 1%Drug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Placebo ControlDrug
The investigational product will be self-applied topically to the affected areas of the face once daily in the evening for 84 consecutive days.
Primary outcomes
What the sponsor says the trial is designed to measure.
- To demonstrate & evaluate the therapeutic, equivalence, and safety of the investigational productTime frame: Baseline to Week 12
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Sun Pharmaceutical Industries, Inc.
Hawthorne, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.